Total
0
Shares
CardieX (ASX:CDX) - CEO & Managing Director, Craig Cooper - The Market Herald
CEO & Managing Director, Craig Cooper
Source: Craig Cooper
  • CardieX's (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology
  • This technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis
  • The new patent further protects CardieX's intellectual property (IP), specifically covering the non-invasive measurement of the heart's pressure
  • The grant of the European patent follows on from similar patents already granted in the U.S. and Japan in 2016
  • CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents

CardieX's (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology.

The SphygmoCor technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis.

It has more than 4500 installations worldwide and is used by major pharmaceutical companies and research institutions such as The Mayo Clinic, Stanford University, and Johns Hopkins.

The new patent further protects CardieX's intellectual property (IP), specifically covering the non-invasive measurement of the heart's pressure and waveform.

This patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease.

The granting of the European patent follows on from similar patents already granted in the United States and Japan in 2016.

"We are very pleased to be granted this new patent to protect our IP in Europe," CEO and Managing Director Craig Cooper said.

"Of great significance is the findings of the examining officers from the EPO, which were similar to the findings we received from examiners in the U.S. in 2016 – that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology," he added.

CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents at 2:00 pm AEST.


Subscribe


CDX by the numbers
More From The Market Herald
Cleanspace (ASX: CSX) - CEO, Dr Alex Birrell - The Market Herald

" CleanSpace (ASX:CSX) shares soar on ASX listing

CleanSpace (CSX) has today listed on the Australian Securities Exchange (ASX) with an initial market capitalisation of $339.7 million.
PainChek (ASX:PCK)- CEO, Philip Daffas (left) - The Market Herald

" PainChek (ASX:PCK) signs partnership deal with disability service provider

PainChek (PCK) has signed its first partnership with a disability service provider Nulsen Group.
Proteomics International Laboratories (ASX:PIQ) - Managing Director, Dr Richard Lipscombe - The Market Herald

" Proteomics International (ASX:PIQ) to raise $6M for high-tech blood test

Proteomics International (PIQ) has received firm commitments to undertake a $6 million share placement.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep’s (ASX:IMM) efti drug to be tested against COVID-19

A novel cancer immunotherapy developed by Immutep (IMM) will be tested in an investigator-initiated clinical trial against COVID-19.